Clinical observation of Sacrubitril/Valsartan in the treatment of heart failure

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025506

Enrollment

Unknown

Registered

2019-08-30

Start date

2018-08-01

Completion date

Unknown

Last updated

2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

experimental group :use Sacrubitril /valsartan

control group:use ACEI

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: HF patients hospitalizing in the department of Cardiology of China-Japan Union hospital of Jilin University from August 2018 to June 2021 were selected.

Exclusion criteria

Exclusion criteria: 1. Acute heart failure; 2. Patients with liver and kidney or other serious organ diseases; 3. With autoimmune diseases; 4. Severe arrhythmia, pericardial tamponade, pulmonary embolism; 5. Severe electrolyte disorders; 6. Severely infected; 7. Pregnant or lactating women; 8. With mental illness; 9. Poor compliance.

Design outcomes

Primary

Measure	Time frame
Electrocardiogram;left ventricular ejection fraction (LVEF);NT-proBNP;	—

Countries

China

Contacts

Public ContactPing Yang

China-Japan Union Hospital of Jilin Universuty

pyang@jlu.edu.cn+86 13944111519

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026